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Abstract
Background: Inborn errors of protein metabolism (IEPM) cause the build-up of
certain amino acid by products in the body. The treatment for IEPMs is a metabolic formula
that eliminates the amino acid that the person with the IEPM cannot metabolize. The purpose
of this study was to determine if patients with an IEPM consuming metabolic formula were
taller than healthy individuals.

Methods: Analysis of height, weight, calories, protein, iron, and vitamin B12 were
compared to height using a regression correlation. Proper growth was determined if the
height-for-age curve was greater than the 50th percentile.

Results: The mean height percentile was 41.23 (p= 0.1885), indicating that the
participants heights were not different from the healthy population. The protein intake
compared to the RDA was significantly different (p< +0.0001). The mean protein intake was
15.89 and intakes were significantly higher than the RDA. Calories, iron, zinc, and vitamin
B-12 intake was compared to the average height percentile and were not correlated to height.

Discussion and Conclusions: There was no significant difference overall in nutrient
intake to height percentile, with protein intake being an exception. The protein intake was
inversely correlated to height, which seems contrary to what one would think, further
investigation is needed.
I

CHAPTER 1
INTRODUCTION
Aminoacidopathies
Inborn errors of protein metabolism (IEPM) are a group of disorders characterized by
the inability of the body to metabolize amino acids. Dietary proteins are hydrolyzed into
amino acids in the gastrointestinal tract. In general, amino acids are further broken down into
𝛼-ketoacids, which can be recycled in the body for generation of energy and other products,
such as glucose, fat, or other amino acids. The breakdown of amino acids to 𝛼-ketoacids
occurs in the liver through a process called transamination.1 During times of stress and illness
the body requires more energy. After the body has exhausted its immediate glucose stores it
will burn fat and muscle for energy. This process of breaking down amino acids into glucose
and the utilization of muscle degradation for energy will increase the levels of amino acids
into the blood.2
Inborn errors of protein metabolism can affect one or more processes involving the
metabolism of amino acids. Serious side effects can result if the problem amino acids are not
restricted to keep blood serum and brain levels within a range consistent with typically
developing individuals. The primary treatment for IEPMs is a low protein diet for life to
ensure the problem amino acid, and its damaging metabolites, are not rising to toxic levels in
the body. These toxic levels can cause a wide array of disabilities, the most notable being
irreversible cognitive delay, due to harmful effects on the brain. Stress caused by infection,
fever or other demands on the body may lead to worsening of the signs and symptoms on
cognitive development, with only partial recovery. 3, 4
1

The severity of IEPMs varies widely; some individuals may be affected severely,
while others may only have mild symptoms. Usually signs and symptoms occur in infancy or
early childhood, however, there is a smaller population that may not show signs and
symptoms of certain disorders until adolescence or even adulthood.3
Each (IEPM) can be characterized by the build-up of certain amino acids as well as
their derivatives. The most common inborn error of protein metabolism is phenylketonuria
(PKU). PKU is characterized by persistent high levels of the essential amino acid,
phenylalanine, and its derivatives, phenylacetate, phenylpyruvate, and phenethylamine,
which can lead to irreversible brain damage.5 Within phenylketonuria, the degree of the
phenylalanine hydroxylase (PAH) deficiency determines the severity of PKU. Severe
intellectual disabilities are the most common and severe side effect of this disease. Similarly,
to other IEPMs, those who do not undergo effective treatment will develop severe
irreversible neurological damage.5 Over time, the neurons in the brain of patients who have
PKU will decrease with excess phenylalanine circulating in the blood, which will cause
neurological dysfunction and cognitive impairment.6
Another IEPM is maple syrup urine disease (MSUD). This disease is characterized by
a buildup of the branched-chain amino acids leucine, isoleucine, and valine.7 The disease
gets its name from the distinct sweet odor that is produced in infants’ urine. Left untreated,
the buildup of the branched-chain amino acids and their ketoacid derivatives can lead to
permanent mental disability, coma, seizures, and death.8 Tyrosinemia is another type of
inborn error of protein metabolism. Tyrosinemia is characterized by the buildup of tyrosine
and its related metabolites, fumarylacetoacetate hydrolase, tyrosine transaminase, 42

hydroxyphenylpyruvate dioxygenase, in the blood. Tyrosinemia, like PKU, can lead to
irreversible cognitive impairment as well as retinol impairment.9 Glutaric acidemia is another
inherited disorder, which is characterized as the body not able to process the amino acids
lysine, hydroxylysine, and tryptophan. Excessive levels of these amino acids and their
intermediates, glutaric acid, glutaryl-CoA, 3-hydroxyglutaric acid, glutaconic acid, and
flavoprotein dehydrogenase, can accumulate and cause damage to the brain, particularly the
basal ganglia, which are regions that help control movement.3 Lastly, Isovaleric Acidemia is
an IEPM characterized by a build-up of leucine and its ketoacid derivatives, which can lead
to permanent intellectual disability as well as coma and death.10 Table 1 gives a brief
description of each IEPM.
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Table 1: IEPMs and their associated amino acid, corresponding derivatives, and side effects
Disease
Amino Acid(s)
5
Phenylketonuria Phenylalanine

Side Effects
Intellectual
disabilities

Tyrosinemia9

Retinol
impairment,
Intellectual
disabilities

Glutaric
Acidemia3

Maple Syrup
Urine Disease7
Isovaleric
Acidemia10

Damaging metabolite(s)
Phenylacetate,
Phenylpyruvate,
Phenethylamine
Tyrosine
Fumarylacetoacetate
Hydrolase, Tyrosine
transaminase, 4hydroxyphenylpyruvate
dioxygenase
Lysine,
Type 1: glutaric acid
Hydroxylysine, glutaryl-CoA, 3Tryptophan
hydroxyglutaric
acid, glutaconic acid
Type 2: flavoprotein
dehydrogenase
Leucine,
Ketoacids
Isoleucine,
Valine
Leucine

Isovaleric Acid

Basal ganglia,
intellectual
disabilities

Lethargy,
Vomiting,
developmental
delay
Seizures,
intellectual
disabilities

The dietary treatment of IEPMs is typically a very restrictive diet, which the patient
will follow for life. This diet requires very low protein consumption from natural foods; the
patients receive most of their protein and calories from a very specific formula, which they
must consume daily for life.11 This formula has a balance of amino acids including the amino
acids they can and cannot metabolize – also including additional amounts of essential amino
acids that may be prevented from being derived through typical enzymatic activity in the
affected patient. Although the patients are receiving most of the calories, protein and
4

micronutrients they need from their formula, they are allowed a certain amount of protein
from natural foods, specified for each patient. Their blood levels and food log analyses
should be regularly monitored to make sure their diet prescription is appropriate.11
Dietary treatment of IEPM protects the brain from toxins that would damage the brain
by keeping the amino acids in a permanent normal range. If there is a delay in treatment for
IEPM there is a greater likelihood for an impaired cognitive outcome. Social outcomes of
patients with IEPM vary due to when the disorder was first diagnosed; but it has been shown
that the longer it takes to diagnose a patient with IEPM the greater likelihood of social
difficulties.12 Due to neurological disadvantages of patients with untreated IEPM, the
academic performance is much lower than that of healthy individuals.12

Height and Nutrition
Nutrition and genetics are the basis for the development of adult height, with nutrition
being most crucial for early childhood growth. According to Dr. Chao-Qiang Lai of the Jean
Mayer U.S. Department of Agriculture Human Nutrition Research Center, genetics only
determines about 60-80% of an individual’s height, while 20-40% is determined by nutrient
intake. The cultural background of an individual will then determine the percentage ratio of
genetics and nutrition compared to height.13
Intake of several micronutrients, as well as protein and total calorie intake, can affect
the likelihood of reaching potential adult height. Some of the major micronutrients tied to
growth and height include, iron, zinc, and vitamin B12.14 – 16 Other micronutrients also
correlated to height development include vitamin A, magnesium, calcium, manganese,
5

potassium, copper, and thiamin.17 Net nutrition is determined through food intake and the
losses to disease and activities. The disease environment is a critical indicator related to adult
height, as patients diagnosed with IEPMs and being treated through metabolic formula have
shown to have normal linear growth compared to those who are not treated.18, 19 Though
there are several aspects to measuring overall health, height is a better indicator of long-term
health rather than weight in children. Height is a gradual component of growth while weight
may fluctuate depending on acute dietary intake. Therefore, height is a more consistent way
of measuring health.20-22
Height-for-age is typically graphed on growth charts provided by the World Health
Organization (WHO) and the Center for Disease Control (CDC). The CDC growth charts
were established by analyzing data from five national health examination surveys and
supplemental data. The percentile curves were developed in two stages using statistical and
graphical measures. The percentiles for height, weight and body mass index (BMI), indicate
if an individual is above or below average compared to the rest of the population for that age.
A point on the 50th percentile indicates the patient is average for their age. A point above or
below the 50th percentile indicates the patient is above average or below average for their
age, respectively. These charts are now a standard tool for most clinics and health care
facilities to graph a patient’s growth.23
An adequate number of calories is well correlated to the height outcomes of children.
In his 2016 study, E. Puentes et al., found that the intake of calories and protein directly
correlates to the height and weight outcome of a child. This study shows protein is needed
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for proper physical development, therefore, suggesting those who have a low protein diet
may be shorter than individuals of their same age with higher protein diets.24
During adolescence iron requirements are also increased. In an experimental study,
Dreizen found that the onset of puberty was delayed by an average of two years in
undernourished, anemic females. The height was also found to be shorter than the healthy
non-anemic individuals.25 Males also require an increased requirement for iron to meet
intended height. This is due to the expansion of blood volume and the rise in hemoglobin
concentrations during growth spurts and puberty.14
Zinc is also major micronutrient involved in height development. Zinc deficiency
reduces the insulin-like growth factor 1 (IGF-1) production and responsiveness, which
correlates to a decrease in growth hormone. Growth hormone is essential for reaching
expected height17, and growth hormone treatment is not as successful if zinc is not also
supplemented. As a result, zinc deficiency is one of the major causes of stunted growth
worldwide.15
Vitamin B12 is another nutrient that is necessary for proper height. Several different
experimental studies concluded that those who received vitamin B12 as a supplement were
taller than those who were not supplemented.16 Infants who are breastfed are less likely to
develop a vitamin B12 deficiency than those who are fed only formula. A lack of vitamin
B12 in the diet may cause an increased risk for neurological disturbances, weakness, and
failure to thrive.26 This is due to vitamin B12’s role in myelination of nerves, an imbalance of
cytokines, and/or accumulation of lactate in cells.27
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Metabolic Formula
Metabolic formulas are designed to help meet the individualized nutrient needs of
patients who have inborn errors of protein metabolism. Each diagnosis requires a unique
mixture of micronutrients to meet the needs of the disorder. For example, phenylketonuria
(PKU) formulas typically have no amount of phenylalanine due to the inability to metabolize
this amino acid. They do contain excess tyrosine to make up for the missing endogenous
production as compared with someone who has a working PAH enzyme.
Each formula is supplemented with vitamins and minerals, which meets or is greater
than the Recommended Dietary Allowances (RDAs) to insure adequate absorption of each
micronutrient.28-29 The RDAs are a guide for estimating the average daily level of intake
sufficient to meet the nutrient requirements of the average person.30 Formula companies have
fortified their formulas to make sure each is providing the right amount of protein, calories,
fat, vitamins, and minerals.28, 29 Studies produced by the United States Department of
Agriculture (USDA) and The National Health and Nutrition Examination Survey (NHANES)
follow the eating habits of healthy children and adolescents. According to both organizations
the average healthy child and/or adolescent is not receiving the recommended dietary amount
of macro- and micronutrients, including the nutrients previously mentioned.31, 32 However,
the patients consuming metabolic formula are receiving almost all their required amounts
through their formula.
Table 2 displays an example of the amounts of macro- and micronutrient intake per
100g of metabolic formula, specifically for PKU patients. Each formula contains relatively
complete nutrition when a person with that same, specific IEPM consumes formulas for a
8

specific IEPM. Due to the relative complete nutrition of a metabolic formula, it could be
argued that a metabolic formula is a more nutritional option than natural foods.33
In 1999, Cerone performed a study to determine the importance of a metabolic diet
for life. After testing 16 non-dieting patients’ neurological functions, intellectual quotient,
and neurological magnetic resonance imaging screenings, the study concluded every patient
had abnormal neurological signs. Therefore, suggesting that metabolic patients should
remain on metabolic formula for life.4

Table 2: Nutrition labels of medical formula per 100grams of powder
Nutrient
Phenex-1

a

Phenylketonuria Metabolic formulas
Phenex-2a
Periflex
Periflex
Junior Plusb Advanceb
410
385
369
30.0
28.0
35.0

PhenylFree 2c
410
22.0

Energy (kcal)
480
Protein equivalents (g)
15
Amino Acids
Phenylalanine (g)
0
0
0
0
0
Tyrosine (g)
1.50
3.00
2.66
3.50
2.20
Carbohydrate (g)
53
35.0
43.2
29.0
60
Fat (g)
21.7
14
12.5
12.6
8.6
Minerals
Calcium (mg)
575
880
980
1035
730
Chloride (mg)
940
406
490
860
Copper (mg)
1.1
1.0
0.56
0.72
1.22
Iodine (µg)
65
100
0.14
115
63
Iron (mg)
9
13
10
12.9
12.2
a. Phenex-2 Amino Acid-Modified Medical Food, Ross Products Division, Columbus, OH.
b. Periflex, Scientific Hospital Supplies, Ltd, Liverpool, England.
c. Phenyl-Free, Mead Johnson Nutritionals, Evansville, IN
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Purpose
The purpose of this study was to determine if the presumed complete nutrition in the
metabolic formulas allowed for differences in height in patients diagnosed with an IEPM as
compared to healthy individuals. Specifically, this study determined if patients who
consumed metabolic formula had heights at or above the 50th percentile for age, and have a
z-score ≥0.
Hypothesis
Individuals with inborn errors of protein metabolism will be taller than the 50th
percentile for height on CDC provided growth charts as well as have a z-score of ≥0 because
they are consuming metabolic formula regularly, which increases their intake of protein,
vitamins, and minerals as compared with the general population.31, 32
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CHAPTER 2

METHODS

Participants
Participants were recruited from the patients seen at the University of Tennessee
Boling Center for Developmental Disabilities as well as Le Bonheur Children’s Hospital.
Participants were chosen based on diagnosis of an inborn error of protein metabolism and
age. These diagnoses include, Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD),
Tyrosinemia Types 1 and 2, Glutaric Acidemia Type 1 (GA1), and Isovaleric Acidemia
(IVA). There were 18 participants, ages 2-20 to allow for plotting of height and body mass
index (BMI) on the WHO and CDC growth charts. The number of participants was
determined by the number of patients seen through both the Boling Center and Le Bonheur.
Each participant was diagnosed with one of the diseases listed above through newborn
screening at birth and have been on metabolic formula since at least 6 months of age.
Participants were not allowed in the study if they did not use metabolic formula for >25% of
their daily calories. During the study, each participant or guardian filled out a questionnaire
regarding patients’ parent’s height and whether each participant met the guidelines to
participate in the study. Prior to the study each participant or guardian was asked to review
the project with benefits and risks explained (Appendix A). This study began after receiving
Institutional Review Board (IRB) approval the University of Tennessee Health Science
Center and University of Memphis (Appendix B).
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Instrumentation
The height of each participant was recorded on a standard growth chart provided by
the Center for Disease Control (CDC) (appendix C) and World Health Organization (WHO)
(appendix D). Z-scores were recorded as provided by WHO. The dietitians on staff
prescribed the metabolic formula, which was provided through a local Durable Medical
Equipment (DME) company. Patients were not asked to change their metabolic formula for
this study.

Procedure
The study was conducted through an observational design. The height and weight of
each participant was recorded using standard scales and stadiometers provided and recorded
by the Boling Center and Le Bonheur registered nurses. The growth curve of each participant
was analyzed, and their growth was from the most recent 5 points on the height-for-age curve
was greater than the 50th percentile. The 5 points were averaged. The 50th percentile is the
average of healthy individuals, so if the participant was above this, then it was concluded that
they are healthier than individuals their same age. The z-scores were also averaged and an
average score of ≥0 was determined. The growth charts were recorded and stored within the
University of Tennessee Boling Center for Developmental Disabilities’ Inborn Errors of
Metabolism nutrition department. Participants’ charts were in room 202B, in a locked filing
cabinet when not being analyzed. The dietitian on staff for both the Boling Center and Le
Bonheur provided a diet prescription to verify metabolic formula was prescribed for each
participant. On the health history form, there were questions regarding the consistency of
12

formula use (Appendix E). Each metabolic formula composition was analyzed to determine
if it supplied adequate amounts of calories, protein, iron, and vitamin B12.
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CHAPTER 3
RESULTS

Analysis was done using a regression correlation between observations made on the
same individual. The alpha level was set at 0.05. There was a total of 18 participants, 11
male and 7 females, 13 with PKU, 4 with MSUD, and 1 with GA. Table 3 displays the
disease, number of participants, and if those participants were at or above the 50th percentile
for height.

Table 3: Participants’ disease states and height ≥50th percentile
IEPM

Number of
participants

Participants at or above
50th percentile for height

%

Phenylkentonuria

13

8

61.5%

4

1

25%

1

1

100%

Maple Syrup
Urine Disease
Glutaric
Acidemia

Patients’ heights were compared to protein intake, calorie intake, and micronutrient
intake (zinc, vitamin B12, and iron), (Table 4). The first test was conducted by looking at the
mean height percentile of each of the 18 participants. The mean height percentile was 41.23
(p = 0.1885). The correlation between height and protein was -0.16. The regression coefficient
of protein was -0.1049, indicating that as protein increases, height decreases.

Mean protein intake was compared to the mean RDA for protein intake. The
difference between the observed protein intake and the RDA protein intake was computed at
14

each data time point. The mean difference in this group was +15.89 (p<0.0001), showing that
participant intake was greater than the RDA.
The mean iron intake was compared to the iron RDA; with the average difference
between the observed and RDA being +3.51, (p = 0.0259), indicating that iron intake that
was higher than the RDA.
Zinc intake was then compared to the zinc RDA. The average difference between zinc
intake and the RDA of zinc intake was +7.64 (p < 0.0001) indicating that zinc intake for this
group was higher than the RDA.
Next, the RDA for vitamin B12 was compared to vitamin B12 intake. The average
difference between B-12 intake in this group and the RDA was +2.99 (p<0.0001), indicating
that intake was greater than RDA.
Lastly, protein, calories, iron, zinc, and vitamin B-12 intake was compared to the
average height percentile. The p-values were 0.003, 0.593, 0.557, 0.551, and 0.793,
respectively, showing that only protein intake was significant.
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Table 4: Statistical analysis and p-values

Comparison

p-value

Mean height vs. 50%ile

0.1885

Iron intake vs. RDA*

0.0259**

Vitamin B12 vs. RDA*

<0.0001**

Zinc vs. RDA*

<0.0001**

Protein intake vs. RDA*

<0.0001**

Protein intake vs. height*

0.003**

Calorie intake vs. height

0.593

Iron vs. height

0.557

Vitamin B12 vs. height

0.793

Zinc vs. height

0.551

*RDA = Recommended Daily Allowance
**indicates significance
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CHAPTER 4
DISCUSSION

There was no significant difference overall in nutrient intake to height percentile with
protein intake being an exception. These results indicate that calories, zinc, iron, and vitamin
B12 did not independently correlate with height; however, there are multiple studies that
suggest intake of these nutrients do affect overall growth.14-19
In several studies iron, zinc, and vitamin B12 have been shown to correlate with
height. 14, 26, 27The expansion of blood volume and the rise in hemoglobin concentrations
during growth spurts and puberty increases the need for iron to meet intended height.14 Zinc
has been found to be an important factor in growth hormone treatment with a zinc deficiency
being a leading cause of stunted growth.15 It has been suggested that a lack of vitamin B12 in
the diet may cause increased risk for failure to thrive. This was a result from comparing
breast fed infants to non-breastfed infants.27

Iron
Iron intake compared to the RDA showed a significance intake of iron through
metabolic formula, revealing the average of children receiving metabolic formula are
receiving their estimated iron needs. However, when iron was compared to height at the 50th
percentile, iron intake did not correlate to height. Other research has indicated iron does
correlate with height outcomes, contrary to this study, due to the blood volume expansion
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and the rise in hemoglobin concentrations during puberty.14 Further research is needed to
clearly define the iron intake and height in children with IEPM.

Zinc
When comparing zinc intake to the zinc, meaning the average participant consuming
metabolic formula, received their estimated daily needs for zinc. However, zinc intake did
not correlate to height. This contradicts the findings of Rivera et. al. who found that zinc
intake does effect height.17

Vitamin B12
The average intake of vitamin B-12 greater than the RDA (p=0.0001) for this group.
Each participant receiving metabolic formula was receiving his or her estimated vitamin B12
needs, however vitamin B12 did not correlate to height. These findings indicate that vitamin
B-12 did not influence height, but this is contrary to other research, which suggests vitamin
B12 does effect height.16, 26, 27 Vitamin B12 deficiency may also cause an increased risk for
neurological disturbances, weakness, and failure to thrive, this affecting adult height.26

Protein
Protein intake compared to the RDA showed that participants ate an average of 15.89
more protein than the RDA for protein. This suggests that each participant receiving
metabolic formula is receiving adequate protein for growth. Additionally, protein compared
to height was the only nutrient that showed significance. This implies protein intake is
18

correlated to height; however, the correlation was inverse, meaning as protein increased
height increased. This is different for other studies suggesting protein intake directly
correlates with height.14-15

Calories
Calorie intake compared to height at or above the 50th percentile revealed no
significance, suggesting calories do not have an impact on height. In one study involving
children and fruit juice consumption, children who consumed more fruit juice had shorter
stature and obesity.34 The children in this study who drank more juice also ate less protein
and milk products, thus the lack of protein might have caused the shorter stature.

Limitations
Data was collected at BCDD and though there were 18 participants, this may not
accurately represent the patients at BCDD. Most patients had the diagnosis of PKU, which
may not be representative of the IEPM population. Additionally, due to the subjectivity of
the diet recall, the nutrient intake may not have been completely accurate. Each participant
may not have been as disciplined with consuming their metabolic formula, which in the early
stages of life can affect the growth outcome of a child with an IEPM.
Further research with more participants over a long period of time, may provide more
information on what affects height in these patients.
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Appendix E
Questionnaire

ASSESSING THE EFFECTS OF METABOLIC FORMULA ON GROWTH
OUTCOMES IN PATIENTS WITH INBORN ERRORS OF PROTEIN
Research Study
Principal Investigator: Emily West
Registered Dietitian/Faculty Advisor: Robert Zach DeBerry
If you have questions about this research study please call Emily at 615-887-4083 or R. Zach
DeBerry at 901-448-6553

Questionnaire
Please answer each question to the best of your ability.
1. What is the patient’s mother’s height? __________
2. What is the patient’s father’s height? __________
3. How many times in the past 6 months did you/your child not finish all of his/her formula?
(circle one)
0 times

1-2 times

3-4 times

5+ times

4. How old were you/your child when you/your child started drinking metabolic formula?
(circle one)
Less than 6 months of age

Greater than 6 months of age

5. Have you/your child had any serious hospitalizations in the last 2 years that has prevented
you/your child from drinking all of your/your child’s formula for a long period of time?
(circle one)
Yes or

No

6. If yes to question 5, how long were you/your child not drinking formula?
(circle one)
1-3 days

4-7 days

1-2 weeks

2+ weeks

IRB NUMBER: 17-05221-XP
IRB APPROVAL DATE: 04/24/2017
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